Skip to content
Dose Brief
Menu
Head-to-head · Brief Score

CoreAge Rx vs Revive Meds

Two GLP-1 desks, one scoreboard. We put CoreAge Rx and Revive Meds head-to-head on the published Brief Score — the same six factors, scored the same way.

Higher Brief ScoreNo. 1 · Grade A

CoreAge Rx

Visit CoreAge Rx Full brief →
vs
No. 233 · Grade C

Revive Meds

Visit Revive Meds Full brief →

The verdict

CoreAge Rx takes this head-to-head.

CoreAge Rx scores 94 to 65 on our six-factor Brief Score — The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.

That doesn't make Revive Meds a bad call — it's best for readers who want pay-per-order compounded glp-1 (with b12) buyers who prepay multi-month for the lowest per-month cost. Weigh the six factors below against your own priorities before you decide.

Why CoreAge Rx leads: it's our #1 on the board — one flat, no-step-up price on both molecules, nationwide, and the steadiest line on our tracker.

Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.

Factor by factor

Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.

Price Stability
97
36
Supply Reliability
95
75
Transparency
90
48
Access Breadth
93
90
Clinical Oversight
92
80
Track Record
88
78
CoreAge RxBrief Score 94 · 65Revive Meds

Price, coverage & the tracker

CoreAge RxRevive Meds
Brief Score94/100 (A)65/100 (C)
Semaglutide$149/moFrom $369/mo (starting dose, compounded)
Tirzepatide$349/moFrom $459/mo (starting dose, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
On the trackerStableprice stableNewnew to the tracker, no prior reading

CoreAge Rx: Flat rate held for a third straight cycle — no first-month teaser to reset.

Revive Meds: New to the tracker on 1 August 2026. The published line reads From $369/mo (starting dose, compounded) at our first reading; there is no earlier reading of ours to compare it against yet.

Keep comparing

Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.